Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00827099 · OUTCOME

Number of Participants With 100 Day Transplant-related Mortality (TRM)

Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer · Source last updated 2012-03-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
100 days

What was measured

100 Day TRM is death within 100 days from transplant related complications

Groups in this outcome

Umbilical Cord Blood Transplant

High dose conditioning with Fludarabine \& Melphalan

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Umbilical Cord Blood Transplant5

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Umbilical Cord Blood Transplant0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      5
    units
    Participants
description
100 Day TRM is death within 100 days from transplant related complications
groups
  1. description
    High dose conditioning with Fludarabine \& Melphalan
    id
    OG000
    title
    Umbilical Cord Blood Transplant
param Type
NUMBER
reporting Status
POSTED
time Frame
100 days
title
Number of Participants With 100 Day Transplant-related Mortality (TRM)
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice